IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
IRONWOOD PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.56+0.06 (+1.71%)
Close on Oct 19, 2026
- Market cap
- $595.16M
- P/E (TTM)
- 4.6
- Dividend yield
- –
IRONWOOD PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative arrangements revenue | $296.15M | $351.41M | $442.74M | $410.60M | $412.78M | $381.55M | $379.65M | $272.84M | $265.53M | $263.92M | 100.0% | -15.7% |
| Collaborative arrangement, other agreements | $87.00K | $734.00K | $2.48M | $1.82M | $1.76M | $1.34M | $1.85M | $1.23M | $419.00K | – | 0.0% | -88.1% |
| Lesinurad | – | – | – | – | – | – | – | – | $3.10M | $3.10M | – | – |
| Sale of active pharmaceutical ingredient | – | – | – | – | $969.00K | $7.98M | $48.76M | $70.36M | $29.68M | $9.93M | – | – |
| Product revenue, net | – | – | – | – | – | – | – | $3.45M | $3.06M | $109.00K | – | – |
| Collaborative arrangement, promotion agreements | – | – | – | – | – | – | $3.70M | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Ironwood Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.